Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Support
This activity is supported by an educational grant from Paratek Pharmaceuticals, Inc.
Medical Crossfire: How Can We Refine Our Approaches to Better Personalize Patient Care in Community-Acquired Bacterial Pneumonia (CABP)?
Release Date: December 14, 2020
Expiration Date: December 14, 2021
Activity Overview
The Medical Crossfire®, one of PER®’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, a panel of 4 multidisciplinary experts explore the impact of community-acquired bacterial pneumonia (CABP) on specific patient populations, and share their approaches for diagnosis, including the use of clinical prediction tools. This lively discussion will help place new treatments that overcome drug-resistant pathogens into clinical context to help you optimize care for your patients with CABP.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Paratek Pharmaceuticals, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This online educational activity is directed toward infectious disease specialists, hospitalists, emergency department physicians, primary care clinicians, pulmonologists, nurse practitioners, nurses, physician assistants, and other health care professionals interested in the treatment of CABP.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss the pathophysiology of drug resistance on the specific patient populations with community-acquired pneumonia (CAP)/CABP
- Review the clinical impact and symptoms that patients with CAP/CABP may experience
- Apply accepted criteria and recommendations in the early diagnosis and evaluation of patients with CABP and severe CABP
- Evaluate the efficacy and safety data of current and developing therapies and therapy selection of antimicrobials for patients with CABP and severe CABP
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty

Professor and Chair, Medicine
Executive Director, Hospitalist Program
University of California, Irvine
Irvine, CA
Disclosures: No relevant financial relationships with commercial interests to disclose.

Assistant Professor of Medicine
Associate Director, Fellowship Program
Department of Pulmonary, Critical Care and Sleep Medicine
New York University Langone Health
New York, NY
Disclosures: No relevant financial relationships with commercial interests to disclose.

Professor of Medicine
Chief, Division of Infectious Diseases
University of Louisville
Louisville, KY
Disclosures: Grant Research Support: Pfizer, Gilead Sciences, Genentech, Sanofi, GlaxoSmithKline, MicroGen; Consultant: Pfizer, Gilead Sciences, MicroGen.

Medical Director, Clinical Decision Unit
Associate Medical Director, Adult Education
Research Director, Emergency Medicine
Associate Professor, Division of Emergency Medicine
Department of Internal Medicine
Morsani College of Medicine
Courtesy Faculty, Department of Anthropology
University of South Florida
Tampa General Hospital
Tampa, FL
Disclosures: No relevant financial relationships with commercial interests to disclose.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.

